To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.

Nan-Chang ChiuHsin ChiYu-Kang TuYa-Ning HuangYu-Lin TaiShun-Long WengLung ChangDaniel Tsung-Ning HuangFu-Yuan HuangChien-Yu Lin

Published in: Expert review of vaccines (2021)

Our systematic review found robust immunogenicity and tolerable reactogenicity of heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants. An additional benefit of stronger T cellular immunity was also observed. Heterologous vaccination is a reasonable and feasible strategy to combat COVID-19. Further studies are warranted to confirm the benefits and identify the optimal combinations, doses, and intervals.

Keyphrases

systematic review
coronavirus disease
sars cov
meta analyses
saccharomyces cerevisiae
randomized controlled trial
case control